Retatrutide cost in 2026: grey market, compounded and after approval

Retatrutide is an investigational drug in Lilly's phase 3 TRIUMPH program. It is not approved by the FDA or any other regulator, it is not on the 503A or 503B bulk substances lists, and it is not the active ingredient of any approved product, which means no US pharmacy can legally compound it. The only product that exists is lyophilized powder sold by research vendors, plus whatever clinics repackage behind a consultation.

That is why every retatrutide price you see is a vendor or marketing figure. The ranges quoted most often in 2026 are roughly 150 to 500 dollars a month for grey market vials at trial doses and roughly 200 to 650 a month through a clinic or telehealth service. The clinic premium buys a consult and a prescription pad, not a different product. How to buy peptides covers what a prescription can and cannot do for an unapproved compound.

Research vendors sell retatrutide in 10, 20 and 30 mg vials, the sizes the compound page lists. On our September 2026 price snapshot, the vendors tracked on the compare page listed 10 mg vials at roughly 30 to 80 dollars, 20 mg vials at roughly 60 to 135, and 30 mg vials at roughly 85 to 200. The spread between the cheapest and most expensive vendor for the same labeled vial was more than double, and those listings change weekly.

Dividing price by labeled mg gives roughly 3 to 7 dollars per mg across the range, with larger vials cheaper per mg at nearly every vendor. That is the number to carry into the monthly math below, with one caution: the mg is what the label says, not what a quantitative assay found. Most vendors publish an HPLC purity percentage and nothing about quantity, and how to read a COA explains why a 99 percent purity figure does not tell you how many mg are in the vial.

The TRIUMPH trials started at 1 or 2 mg weekly and escalated every 4 weeks toward maintenance doses of 4, 8 or 12 mg, and the retatrutide dosage chart lays out the schedule. A month is about 4.3 weeks, so 4 mg weekly uses about 17 mg a month, 8 mg weekly about 35 mg, and 12 mg weekly about 52 mg. At 3 to 7 dollars per labeled mg, that works out to roughly 50 to 120 dollars a month at 4 mg, 105 to 245 at 8 mg, and 155 to 365 at 12 mg.

That is below the commonly quoted 150 to 500 range at the low doses and inside it at the top, and the gap is explained by waste and by vendor choice. A reconstituted vial should be used within about 4 weeks. A 20 mg vial at 2 mg weekly lasts 10 weeks on paper, so more than half of it expires unused, and the real cost per injected mg roughly doubles. Buying 10 mg vials avoids the waste at low doses and costs more per mg; buying 20 or 30 mg vials saves per mg and only pays off once the dose reaches 5 mg weekly or more.

The titration period also costs less than maintenance. The first two months at 1 to 4 mg use about 10 to 15 mg in total, which a single 10 or 20 mg vial covers. People who quote a cheap first month and find the bill tripling by month four are discovering the dose ladder, not a price change. The calculator shows how long any vial lasts at a given dose.

The useful comparison is against the drugs people would otherwise use. Compounded tirzepatide through telehealth is commonly quoted at roughly 250 to 400 dollars a month. Lilly's self pay Zepbound vials are commonly quoted at roughly 349 to 499 a month depending on the dose. Grey market retatrutide at 150 to 500 overlaps both, and at the lower trial doses it is cheaper than either.

What the cheaper number leaves out is everything the approved product includes. Zepbound is a labeled, sterile product with the mg on the vial verified, a prescriber attached, and a safety database of tens of thousands of trial participants. Retatrutide from a vendor is an unverified powder of an unapproved drug with limited long term safety data, a heart rate signal that is larger than tirzepatide's, and no clinician in the loop. The retatrutide vs tirzepatide comparison goes through efficacy and safety; on the cost side, retatrutide is cheaper per month because it is sold without any of the things that make tirzepatide expensive.

There is also a timing argument. Tirzepatide's compounded supply is in question, since the FDA proposed removing it from the 503B bulks list in April 2026 and no final decision has been reported. Retatrutide's grey market supply has no legal supply to be removed from, which is either its strength or its warning.

Lilly reported positive TRIUMPH topline results in 2026, with about 28 percent average weight loss over 80 weeks at 12 mg in TRIUMPH-1, and said it plans to file for FDA approval in the first quarter of 2027. Approval, if it comes, is therefore not expected before late 2027 at the earliest. Those are sponsor reported figures pending full publication, and the phase 3 results explainer covers what is and is not known.

Nothing has been announced about price, and anything written about it is speculation. Analysts have generally expected Lilly to price an approved retatrutide in the same territory as Zepbound, possibly with a premium for the larger weight loss, and to offer a self pay vial program as it did for tirzepatide. That is a guess built on Lilly's past behavior, not information. A list price above 1,000 dollars a month with inconsistent insurance coverage would fit the pattern of the two drugs before it.

What approval would change for certain is the product. An approved retatrutide would have a verified concentration, sterility testing, a label with a titration schedule, and a prescriber. It would also, in time, put pressure on the grey market, the way self pay Zepbound vials narrowed the gap with compounded tirzepatide. Until then the only retatrutide available is the research vial, and the only price is whatever the vendor charges this week.

Retatrutide is a 39 amino acid lipidated peptide, which is difficult and expensive to synthesize well. There is no pharmacopeial monograph for it, so a vendor COA compares the vial with whatever reference material the testing lab had rather than with an official standard. Purity figures from different labs are therefore not directly comparable, and an identity claim is only as good as the lab's reference. The compound page is blunt about it: purity, concentration and even identity vary between suppliers.

This matters more for retatrutide than for a cheap healing peptide because the dose is titrated by response and the side effects are dose dependent. An underfilled vial that delivers 2 mg when the syringe says 4 produces a weak response, the person steps up, and the next vial from a different batch delivers the full amount on top of a jump. The glucagon component makes the early weeks rough at the best of times, and the heart rate rise the trials reported is not something to meet unexpectedly.

The cost advice follows from that. The cheapest listed vial is only cheaper if it contains what the label says. A vendor with mass spec identity, a quantity assay and a lot number that matches the certificate is worth paying more per mg for, and the vendor reviews note which ones publish that. Whatever the route, retatrutide in 2026 is an investigational drug used without supervision, and the price is the smallest part of that decision.